LOVAZA- omega-3-acid ethyl esters capsule, liquid filled

Riik: Ameerika Ühendriigid

keel: inglise

Allikas: NLM (National Library of Medicine)

Osta kohe

Toote omadused Toote omadused (SPC)
04-09-2020

Toimeaine:

OMEGA-3-ACID ETHYL ESTERS (UNII: D87YGH4Z0Q) (OMEGA-3 FATTY ACIDS - UNII:71M78END5S)

Saadav alates:

GlaxoSmithKline LLC

INN (Rahvusvaheline Nimetus):

OMEGA-3-ACID ETHYL ESTERS

Koostis:

OMEGA-3-ACID ETHYL ESTERS 900 mg

Manustamisviis:

ORAL

Retsepti tüüp:

PRESCRIPTION DRUG

Näidustused:

LOVAZA (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving LOVAZA and should continue this diet during treatment with LOVAZA. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with LOVAZA. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed, if possible, prior to consideration of TG-lowering drug therapy. Limitations of Use: The effect of LOVAZA on the risk for pancreatitis has not

Toote kokkuvõte:

LOVAZA (omega-3-acid ethyl esters) capsules are supplied as 1-gram, transparent, soft-gelatin capsules filled with light-yellow oil and bearing the designation “GS FH2”. Bottles of 120: NDC 0173-0884-08. Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Do not freeze. Keep out of reach of children.

Volitamisolek:

New Drug Application

Toote omadused

                                LOVAZA- OMEGA-3-ACID ETHYL ESTERS CAPSULE, LIQUID FILLED
GLAXOSMITHKLINE LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LOVAZA SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR LOVAZA.
LOVAZA (OMEGA-3-ACID ETHYL ESTERS CAPSULES), FOR ORAL USE
INITIAL U.S. APPROVAL: 2004
INDICATIONS AND USAGE
LOVAZA is a combination of ethyl esters of omega 3 fatty acids,
principally eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), indicated as an adjunct to diet to reduce
triglyceride (TG) levels in adult patients with severe
(≥500 mg/dL) hypertriglyceridemia. (1)
Limitations of Use:
•
•
DOSAGE AND ADMINISTRATION
•
•
DOSAGE FORMS AND STRENGTHS
Capsules: 1 gram (3)
CONTRAINDICATIONS
LOVAZA is contraindicated in patients with known hypersensitivity
(e.g., anaphylactic reaction) to LOVAZA or any of its
components. (4)
WARNINGS AND PRECAUTIONS
•
•
•
•
ADVERSE REACTIONS
The most common adverse reactions (incidence >3% and greater than
placebo) were eructation, dyspepsia, and taste
perversion. (6)
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT GLAXOSMITHKLINE AT
1-888-825-5249 OR FDA AT 1-800-
FDA-1088 OR WWW.FDA.GOV/MEDWATCH.
DRUG INTERACTIONS
Omega-3-acids may prolong bleeding time. Patients taking LOVAZA and an
anticoagulant or other drug affecting
coagulation (e.g., anti-platelet agents) should be monitored
periodically. (7.1)
SEE 17 FOR PATIENT COUNSELING INFORMATION AND FDA-APPROVED PATIENT
LABELING.
REVISED: 9/2020
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
The effect of LOVAZA on the risk for pancreatitis has not been
determined. (1)
The effect of LOVAZA on cardiovascular mortality and morbidity has not
been determined. (1)
The daily dose of LOVAZA is 4 grams per day taken as a single 4-gram
dose (4 capsules) or as two 2-gram doses (2
capsules given twice daily). (2)
Patients should be advised to swallow LOVAZA capsules whole. Do not
break open, crush, dissolve, or chew
                                
                                Lugege kogu dokumenti
                                
                            

Otsige selle tootega seotud teateid